Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens

Chien An Chen, Chun Ju Chiang, Yun Yuan Chen, San Lin You, Shu Feng Hsieh, Chao Hsiun Tang, Wen Fang Cheng

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established. Methods: Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3–6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined. Results: A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p<0.001) or PT regimens (p=0.001). Additionally, patients >50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3–5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050). Conclusion: Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.

Original languageEnglish
Article numbere16
JournalJournal of Gynecologic Oncology
Volume29
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Paclitaxel
Cyclophosphamide
Carcinoma
Survival
Ovarian Neoplasms
Disease-Free Survival
Platinum
National Health Programs
Adjuvant Chemotherapy
Taiwan
Databases

Keywords

  • Disease-Free Survival
  • Drug Therapy
  • Ovarian Neoplasms
  • Survival
  • Taxane

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Cite this

Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens. / Chen, Chien An; Chiang, Chun Ju; Chen, Yun Yuan; You, San Lin; Hsieh, Shu Feng; Tang, Chao Hsiun; Cheng, Wen Fang.

In: Journal of Gynecologic Oncology, Vol. 29, No. 1, e16, 01.01.2018.

Research output: Contribution to journalArticle

Chen, Chien An ; Chiang, Chun Ju ; Chen, Yun Yuan ; You, San Lin ; Hsieh, Shu Feng ; Tang, Chao Hsiun ; Cheng, Wen Fang. / Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens. In: Journal of Gynecologic Oncology. 2018 ; Vol. 29, No. 1.
@article{4855e59ab0654e88ac73bfb17ef8bcfa,
title = "Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens",
abstract = "Objective: Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established. Methods: Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3–6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined. Results: A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0{\%} vs. 77.6{\%}; p=0.410) and OS (84.6{\%} vs. 84.3{\%}; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p<0.001) or PT regimens (p=0.001). Additionally, patients >50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3–5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050). Conclusion: Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.",
keywords = "Disease-Free Survival, Drug Therapy, Ovarian Neoplasms, Survival, Taxane",
author = "Chen, {Chien An} and Chiang, {Chun Ju} and Chen, {Yun Yuan} and You, {San Lin} and Hsieh, {Shu Feng} and Tang, {Chao Hsiun} and Cheng, {Wen Fang}",
year = "2018",
month = "1",
day = "1",
doi = "10.3802/jgo.2018.29.e16",
language = "English",
volume = "29",
journal = "Journal of Gynecologic Oncology",
issn = "2005-0380",
publisher = "Korean Society of Gynecologic Oncology and Colposcopy",
number = "1",

}

TY - JOUR

T1 - Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens

AU - Chen, Chien An

AU - Chiang, Chun Ju

AU - Chen, Yun Yuan

AU - You, San Lin

AU - Hsieh, Shu Feng

AU - Tang, Chao Hsiun

AU - Cheng, Wen Fang

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established. Methods: Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3–6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined. Results: A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p<0.001) or PT regimens (p=0.001). Additionally, patients >50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3–5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050). Conclusion: Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.

AB - Objective: Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established. Methods: Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3–6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined. Results: A total of 1,510 early-stage OC patients, including 841 who received CP regimen and 699 who received PT regimen, were included. The 2 groups had a similar estimated probability of 5-year DFS (PT vs. CP, 79.0% vs. 77.6%; p=0.410) and OS (84.6% vs. 84.3%; p=0.691). Patients >50 years of age who received the CP regimen had a lower 5-year DFS than the patients ≤50 years of age who received the CP (p<0.001) or PT regimens (p=0.001). Additionally, patients >50 years of age who received the CP regimen had a worse 5-year OS compared with the other 3 groups (p=0.019) (p=0.179 for patients >50 years of age in the PT group; p=0.002 for patients ≤50 years of age in the CP group; and p=0.061 for patients ≤50 years of age in the PT group). Patients with the CP or PT regimen for 3–5 cycles had a similar 5-year DFS and OS compared to 6 cycles (p>0.050). Conclusion: Chemotherapeutic regimens with taxane could be recommended for early-stage OC patients >50 years of age.

KW - Disease-Free Survival

KW - Drug Therapy

KW - Ovarian Neoplasms

KW - Survival

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=85036536930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036536930&partnerID=8YFLogxK

U2 - 10.3802/jgo.2018.29.e16

DO - 10.3802/jgo.2018.29.e16

M3 - Article

AN - SCOPUS:85036536930

VL - 29

JO - Journal of Gynecologic Oncology

JF - Journal of Gynecologic Oncology

SN - 2005-0380

IS - 1

M1 - e16

ER -